Overview

Carisma Therapeutics is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

08 May '23
PHILADELPHIA , May 8, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) (" Carisma " or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer,

Events

Corporate Presentation